[
    {
        "headline": "Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline results expected in July 2025. NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today provided an update on its obstructive sleep ap"
    },
    {
        "headline": "Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Topline Phase 2 clinical data expected in the first half 2025NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combina"
    },
    {
        "headline": "Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules",
        "text": "Funds to support the advancement of Incannex’s IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.NEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced that it has entered into security purchase agreement"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates",
        "text": "Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financia"
    },
    {
        "headline": "Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board",
        "text": "Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovationNEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed."
    },
    {
        "headline": "Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea",
        "text": "Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure levels of IHL-42X and the reference listed drugs (RLD) for dronabinol and acetazolamide, building a scientific bridge to established safety and toxicology data with the potential to support a future FDA 505(b)(2) new drug application (NDA)Pharmacokinetic results for IHL-42X will inform analysis of a"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of $0.3M from 1Q24. We expect R&D costs to continue to climb as the Company focuses on getting its drug candidates ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates",
        "text": "NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial results and provided business highlights for the quarter ended September 30, 2024. “The first quarter reflects ongoing progress for Incannex, building on the momentum of a transformative"
    },
    {
        "headline": "Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer",
        "text": "NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato’s drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals,"
    },
    {
        "headline": "Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks",
        "text": "As major U.S. stock indexes experience slight declines, investors are keenly analyzing earnings reports and economic indicators to gauge the market's direction. In this context, penny stocks continue to capture attention for their potential value, despite being a term that may seem outdated. These smaller or newer companies can offer compelling investment opportunities when they exhibit strong financial foundations, and we will explore several such stocks that stand out in the current market..."
    },
    {
        "headline": "Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)",
        "text": "Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates",
        "text": "Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of PSX-001, known as the PsiGAD1 study, in which synthetic psilocybin in combination with psychotherapy was observed to significantly reduce anxiety scores and to be well tolerated in patients with generalised anxiety disorder (GAD) Commenced dosing in the RePOSA Phase 2/3 clinical trial"
    },
    {
        "headline": "Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors",
        "text": "Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of CreditNEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developing life-changing medicines for people with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to $10 million in secured convertible note"
    },
    {
        "headline": "Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives",
        "text": "A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment. New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a new survey entitled \"Understanding Obstructive Sleep Apnea Treatment Experiences and Patient Perspectives.\" Accordi"
    },
    {
        "headline": "FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed",
        "text": "Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product.PsiGAD2, short for Psilocybin for Generalised Anxiety Disorder trial two, follows the PsiGAD1 proof of concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Sacle (HAM-A) score from baseline in the psilocybin treatment group. NEW YORK and MELBOU"
    },
    {
        "headline": "Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X",
        "text": "IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone.bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan.Analysis of data underway, however, no serious adverse events were reported.Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing co"
    },
    {
        "headline": "Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea",
        "text": "NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA’). IHL-42X is the Company’s proprietary fixed dose comb"
    },
    {
        "headline": "Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline results expected in July 2025. NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today provided an update on its obstructive sleep ap"
    },
    {
        "headline": "Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Topline Phase 2 clinical data expected in the first half 2025NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combina"
    },
    {
        "headline": "Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules",
        "text": "Funds to support the advancement of Incannex’s IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.NEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced that it has entered into security purchase agreement"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates",
        "text": "Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financia"
    },
    {
        "headline": "Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board",
        "text": "Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovationNEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed."
    },
    {
        "headline": "Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea",
        "text": "Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure levels of IHL-42X and the reference listed drugs (RLD) for dronabinol and acetazolamide, building a scientific bridge to established safety and toxicology data with the potential to support a future FDA 505(b)(2) new drug application (NDA)Pharmacokinetic results for IHL-42X will inform analysis of a"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of $0.3M from 1Q24. We expect R&D costs to continue to climb as the Company focuses on getting its drug candidates ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates",
        "text": "NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial results and provided business highlights for the quarter ended September 30, 2024. “The first quarter reflects ongoing progress for Incannex, building on the momentum of a transformative"
    },
    {
        "headline": "Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer",
        "text": "NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato’s drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals,"
    },
    {
        "headline": "Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks",
        "text": "As major U.S. stock indexes experience slight declines, investors are keenly analyzing earnings reports and economic indicators to gauge the market's direction. In this context, penny stocks continue to capture attention for their potential value, despite being a term that may seem outdated. These smaller or newer companies can offer compelling investment opportunities when they exhibit strong financial foundations, and we will explore several such stocks that stand out in the current market..."
    },
    {
        "headline": "Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)",
        "text": "Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates",
        "text": "Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of PSX-001, known as the PsiGAD1 study, in which synthetic psilocybin in combination with psychotherapy was observed to significantly reduce anxiety scores and to be well tolerated in patients with generalised anxiety disorder (GAD) Commenced dosing in the RePOSA Phase 2/3 clinical trial"
    },
    {
        "headline": "Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors",
        "text": "Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of CreditNEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developing life-changing medicines for people with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to $10 million in secured convertible note"
    },
    {
        "headline": "Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives",
        "text": "A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment. New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a new survey entitled \"Understanding Obstructive Sleep Apnea Treatment Experiences and Patient Perspectives.\" Accordi"
    },
    {
        "headline": "FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed",
        "text": "Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product.PsiGAD2, short for Psilocybin for Generalised Anxiety Disorder trial two, follows the PsiGAD1 proof of concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Sacle (HAM-A) score from baseline in the psilocybin treatment group. NEW YORK and MELBOU"
    },
    {
        "headline": "Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X",
        "text": "IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone.bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan.Analysis of data underway, however, no serious adverse events were reported.Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing co"
    },
    {
        "headline": "Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea",
        "text": "NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA’). IHL-42X is the Company’s proprietary fixed dose comb"
    },
    {
        "headline": "Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline results expected in July 2025. NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today provided an update on its obstructive sleep ap"
    },
    {
        "headline": "Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Topline Phase 2 clinical data expected in the first half 2025NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combina"
    },
    {
        "headline": "Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules",
        "text": "Funds to support the advancement of Incannex’s IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.NEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced that it has entered into security purchase agreement"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates",
        "text": "Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financia"
    },
    {
        "headline": "Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board",
        "text": "Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovationNEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed."
    },
    {
        "headline": "Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea",
        "text": "Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure levels of IHL-42X and the reference listed drugs (RLD) for dronabinol and acetazolamide, building a scientific bridge to established safety and toxicology data with the potential to support a future FDA 505(b)(2) new drug application (NDA)Pharmacokinetic results for IHL-42X will inform analysis of a"
    },
    {
        "headline": "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025",
        "text": "Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of $0.3M from 1Q24. We expect R&D costs to continue to climb as the Company focuses on getting its drug candidates ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates",
        "text": "NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial results and provided business highlights for the quarter ended September 30, 2024. “The first quarter reflects ongoing progress for Incannex, building on the momentum of a transformative"
    },
    {
        "headline": "Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer",
        "text": "NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato’s drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals,"
    },
    {
        "headline": "Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks",
        "text": "As major U.S. stock indexes experience slight declines, investors are keenly analyzing earnings reports and economic indicators to gauge the market's direction. In this context, penny stocks continue to capture attention for their potential value, despite being a term that may seem outdated. These smaller or newer companies can offer compelling investment opportunities when they exhibit strong financial foundations, and we will explore several such stocks that stand out in the current market..."
    },
    {
        "headline": "Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)",
        "text": "Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: ..."
    },
    {
        "headline": "Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates",
        "text": "Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of PSX-001, known as the PsiGAD1 study, in which synthetic psilocybin in combination with psychotherapy was observed to significantly reduce anxiety scores and to be well tolerated in patients with generalised anxiety disorder (GAD) Commenced dosing in the RePOSA Phase 2/3 clinical trial"
    },
    {
        "headline": "Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors",
        "text": "Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of CreditNEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developing life-changing medicines for people with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to $10 million in secured convertible note"
    },
    {
        "headline": "Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives",
        "text": "A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment. New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a new survey entitled \"Understanding Obstructive Sleep Apnea Treatment Experiences and Patient Perspectives.\" Accordi"
    },
    {
        "headline": "FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed",
        "text": "Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product.PsiGAD2, short for Psilocybin for Generalised Anxiety Disorder trial two, follows the PsiGAD1 proof of concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Sacle (HAM-A) score from baseline in the psilocybin treatment group. NEW YORK and MELBOU"
    },
    {
        "headline": "Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X",
        "text": "IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone.bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan.Analysis of data underway, however, no serious adverse events were reported.Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing co"
    },
    {
        "headline": "Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea",
        "text": "NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA’). IHL-42X is the Company’s proprietary fixed dose comb"
    },
    {
        "headline": "Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)",
        "text": "Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline results expected in July 2025. NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today provided an update on its obstructive sleep ap"
    }
]